MCID: ULC008
MIFTS: 23

Ulcerative Proctitis malady

Categories: Rare diseases, Gastrointestinal diseases

Aliases & Classifications for Ulcerative Proctitis

About this section

Aliases & Descriptions for Ulcerative Proctitis:

Name: Ulcerative Proctitis 48
 
Chronic Ulcerative Proctitis 68

Classifications:



External Ids:

ICD1030 K51.2

Summaries for Ulcerative Proctitis

About this section
NIH Rare Diseases:48 Ulcerative proctitis is a type of ulcerative colitis that affects the rectum. The symptoms of this form of proctitis may include bleeding from the rectum, the need to go to the bathroom frequently, tenesmus, diarrhea or constipation, and rectal pain. People with ulcerative proctitis tend to have episodes when the symptoms worsen and periods without symptoms, although the course of the disease varies among affected individuals. Treatment involves applying 5-aminosalicylic acid (5-ASA) or steroid creams to the rectum. In some cases, an oral version of 5-ASA is used to prevent episodes. Last updated: 12/11/2012

MalaCards based summary: Ulcerative Proctitis, also known as chronic ulcerative proctitis, is related to proctitis and colitis, and has symptoms including rectal inflammations nec and pathergy reaction. An important gene associated with Ulcerative Proctitis is CRP (C-Reactive Protein). Affiliated tissues include colon and monocytes.

Related Diseases for Ulcerative Proctitis

About this section

Diseases related to Ulcerative Proctitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
idRelated DiseaseScoreTop Affiliating Genes
1proctitis10.7
2colitis10.2
3ulcerative colitis10.2
4systemic lupus erythematosus9.7
5crohn's disease9.7
6hemolytic anemia9.7
7neutropenia9.7
8lymphogranuloma venereum9.7
9pericarditis9.7
10constipation9.7
11intestinal pseudo-obstruction9.7
12lupus erythematosus9.7
13rectal prolapse9.7
14lymphomatoid papulosis9.7
15cytomegalovirus infection9.7

Graphical network of diseases related to Ulcerative Proctitis:



Diseases related to ulcerative proctitis

Symptoms & Phenotypes for Ulcerative Proctitis

About this section

UMLS symptoms related to Ulcerative Proctitis:


rectal inflammations nec, pathergy reaction

Drugs & Therapeutics for Ulcerative Proctitis

About this section

Drugs for Ulcerative Proctitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SucralfateapprovedPhase 41054182-58-0
Synonyms:
Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminum
Sucralfat
 
Sucralfate
Sucralfato
Sucralfatum
2
Tacrolimusapproved, investigationalPhase 4, Phase 21074104987-11-3445643, 439492
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
AKOS005145901
Advagraf
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
BCBcMAP01_000194
BRD-K35452788-001-02-1
BSPBio-001279
BSPBio_001279
Bio-0921
Bio2_000470
Bio2_000950
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
CPD-10016
CPD000466356
D08556
DB00864
DivK1c_001040
FK 506
FK-506
FK5
FK506
FR 900506
FR-900506
 
FR900506
FT-0082660
Fk-506
Fujimycin
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus (anhydrous)
Tacrolimus anhydrous
Tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
nchembio.2007.23-comp2
tacrolimus
tacrolimus hydrate
3Calcineurin InhibitorsPhase 4, Phase 21597
4Anti-Ulcer AgentsPhase 41767
5Gastrointestinal AgentsPhase 4, Phase 28109
6Immunosuppressive AgentsPhase 4, Phase 212770
7AntacidsPhase 41767
8
BudesonideapprovedPhase 3, Phase 242251333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide MMX
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
Horacort
 
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
9AnalgesicsPhase 3, Phase 211287
10Peripheral Nervous System AgentsPhase 3, Phase 222776
11Respiratory System AgentsPhase 3, Phase 24818
12MesalaminePhase 3, Phase 216089-57-6
13Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 212767
14Antirheumatic AgentsPhase 3, Phase 210627
15Anti-Inflammatory Agents, Non-SteroidalPhase 3, Phase 24295
16Analgesics, Non-NarcoticPhase 3, Phase 26260
17Hormone AntagonistsPhase 3, Phase 212778
18HormonesPhase 3, Phase 213979
19Anti-Asthmatic AgentsPhase 3, Phase 23369
20Autonomic AgentsPhase 3, Phase 29774
21Anti-Inflammatory AgentsPhase 3, Phase 210355
22Bronchodilator AgentsPhase 3, Phase 22856
23glucocorticoidsPhase 3, Phase 24920
24ColaNutraceuticalPhase 3, Phase 21881
25
Propofolapproved, investigational, vet_approvedPhase 210282078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
26
Midazolamapproved, illicitPhase 268459467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
 
Dormicum
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
27
BisacodylapprovedPhase 270603-50-9
Synonyms:
Bisacodilo
Bisacodyl
Bisacodyle
 
Bisacodylum
Dulcolax
Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)
Spirolax
28
Fentanylapproved, illicit, investigational, vet_approvedPhase 2773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
29OrangeNutraceuticalPhase 2249

Interventional clinical trials:

(show all 16)
idNameStatusNCT IDPhase
1Rectal Tacrolimus in the Treatment of Resistant Ulcerative ProctitisCompletedNCT01418131Phase 4
2Combined Therapy in Radiation ProctopathyCompletedNCT01613534Phase 4
3The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or ProctosigmoiditisCompletedNCT01349673Phase 3
4Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisCompletedNCT01008423Phase 3
5Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or ProctosigmoiditisCompletedNCT01008410Phase 3
6Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative ProctitisTerminatedNCT01016262Phase 3
7Clinical Trial With Mesalamine 1g SuppositoriesTerminatedNCT01172444Phase 3
8Safety, Tolerability, Biomarker and Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative ColitisUnknown statusNCT01149707Phase 2
9Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative ProctitisCompletedNCT01837615Phase 2
10Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative ProctitisCompletedNCT01966783Phase 2
11Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.CompletedNCT02104271Phase 2
12Medical Treatment of Colitis in Patients With Hermansky-Pudlak SyndromeWithdrawnNCT00514982Phase 2
13Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis DiseaseCompletedNCT02025777
14Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of TreatmentCompletedNCT01684514
15QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)RecruitingNCT02368743
16Phenomics in Autoimmune and Inflammatory DiseasesRecruitingNCT02466217

Search NIH Clinical Center for Ulcerative Proctitis

Genetic Tests for Ulcerative Proctitis

About this section

Anatomical Context for Ulcerative Proctitis

About this section

MalaCards organs/tissues related to Ulcerative Proctitis:

36
Colon, Monocytes

Publications for Ulcerative Proctitis

About this section

Articles related to Ulcerative Proctitis:

(show top 50)    (show all 102)
idTitleAuthorsYear
1
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. (27489240)
2016
2
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications. (27446860)
2016
3
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study. (28089625)
2016
4
Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. (26663677)
2016
5
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. (27416045)
2016
6
A case of appendectomy as main therapeutic intervention for complex co-morbid ulcerative proctitis. (25690705)
2015
7
Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. (25644096)
2015
8
Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. (26386854)
2015
9
P214. Ulcerative Proctitis: Predictors and outcomes of disease extension in UC. (25717682)
2015
10
P587. Tacrolimus suppositories in therapy-resistant ulcerative proctitis - a single center experience. (25718087)
2015
11
P461. Therapeutic requirements and health resources in the treatment of clinically active ulcerative proctitis. (25717954)
2015
12
Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. (25687266)
2015
13
Oral 5-aminosalicylate, mesalamine suppository and mesalamine enema as initial therapy for ulcerative proctitis in clinical practice with quality of care implications. (26469062)
2015
14
Improvement of Refractory Ulcerative Proctitis With Sacral Nerve Stimulation. (25930972)
2015
15
Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. (26185880)
2014
16
Ulcerative proctitis: an update on the pharmacotherapy and management. (24837209)
2014
17
Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis. (25072502)
2014
18
Proximal disease extension and related predicting factors in ulcerative proctitis. (24325564)
2014
19
Gastrointestinal symptoms resembling ulcerative proctitis caused by larvae of the drone fly Eristalis tenax. (24766340)
2014
20
Ulcerative proctitis in out-patient practice: an unexpected clinical challenge. (25176055)
2014
21
Comparison of Xilei-san, a Chinese herbal medicine, and dexamethasone in mild/moderate ulcerative proctitis: a double-blind randomized clinical trial. (23383973)
2013
22
A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. (22715829)
2012
23
Placebo controlled evaluation of Xilei San, a herbal preparation in patients with intractable ulcerative proctitis. (22775479)
2012
24
Expanding the therapeutic armamentarium of ulcerative proctitis. (23167520)
2012
25
Psoriatic colitis mimicking ulcerative proctitis in an elderly patient. (22884084)
2012
26
Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study. (22690748)
2012
27
Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued? (23576086)
2012
28
Appendicectomy as a potential therapy for refractory ulcerative proctitis. (21679209)
2011
29
A multicenter, randomized study to evaluate the efficacy and safety of mesalamine suppositories 1 g at bedtime and 500 mg Twice daily in patients with active mild-to-moderate ulcerative proctitis. (20676771)
2011
30
Hydrogen peroxide exposure mimicking ulcerative proctitis. (21130717)
2011
31
Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. (20848454)
2010
32
Recurrent pericarditis in a patient with ulcerative proctitis due to mesalazine suppositories. (20237787)
2010
33
Infliximab for refractory ulcerative proctitis. (20222911)
2010
34
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. (20310020)
2010
35
Appendicectomy as a therapy for ulcerative proctitis. (19584834)
2009
36
Emerging issues in ulcerative colitis and ulcerative proctitis: individualizing treatment to maximize outcomes. (20574506)
2009
37
Topically administered infliximab can work in ulcerative proctitis despite the ineffectiveness of intravenous induction therapy. (19436284)
2009
38
Ulcerative proctitis: a review of pharmacotherapy and management. (18345952)
2008
39
Appendiceal orifice inflammation and ulcerative proctitis. (18674731)
2008
40
Rectal tacrolimus in the treatment of resistant ulcerative proctitis. (18761706)
2008
41
A combination of rectal beclomethasone diproprionate and mesalazine in ulcerative proctitis. (18415762)
2008
42
A suppository Chinese medicine (xilei-san) for refractory ulcerative proctitis: a pilot clinical trial. (17675886)
2007
43
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis. (16393311)
2006
44
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. (17012969)
2006
45
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. (17012968)
2006
46
Colorectal motor and sensitivity features in patients affected by ulcerative proctitis with constipation: a radiological and manometric controlled study. (16917226)
2006
47
Ulcerative proctitis in men who have sex with men: an emerging outbreak. (16410585)
2006
48
Ulcerative proctitis. (20011281)
2004
49
Granulocyte, macrophage, monocyte apheresis for refractory ulcerative proctitis. (15316424)
2004
50
Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis. (15626890)
2004

Variations for Ulcerative Proctitis

About this section

Expression for genes affiliated with Ulcerative Proctitis

About this section
Search GEO for disease gene expression data for Ulcerative Proctitis.

Pathways for genes affiliated with Ulcerative Proctitis

About this section

GO Terms for genes affiliated with Ulcerative Proctitis

About this section

Sources for Ulcerative Proctitis

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet